Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Phase 2

Recruiting

Conditions: Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Lymphoblastic Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Drug: Cytarabine
Drug: Calaspargase Pegol
Procedure: Echocardiography
Drug: Fludarabine Phosphate
Drug: Hydrocortisone Sodium Succinate
Procedure: Lumbar Puncture
Drug: Methotrexate
Procedure: Multigated Acquisition Scan
Drug: Prednisolone
Drug: Prednisone
Drug: Revumenib
Drug: Vincristine Sulfate

First Posted Date: 2023-03-09

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 78

Registration Number: NCT05761171

Locations: 🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States
🇺🇸
Renown Regional Medical Center, Reno, Nevada, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 62 locations

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

Phase 3

Recruiting

Conditions: Takayasu Arteritis

Interventions: Drug: Tofacitinib 5 MG
Drug: Prednisolone
Other: Placebo of prednisolone
Other: Placebo of tofacitinib 5mg

First Posted Date: 2023-03-01

Last Posted Date: 2023-03-01

Lead Sponsor: Chinese SLE Treatment And Research Group

Target Recruit Count: 50

Registration Number: NCT05749666

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages

Phase 4

Recruiting

Conditions: Habitual Abortion
Miscarriage
Recurrent Pregnancy Loss
Fertility Disorders
Recurrent Miscarriage

Interventions: Drug: Placebo
Drug: Prednisolone

First Posted Date: 2023-02-13

Last Posted Date: 2024-05-24

Lead Sponsor: Leiden University Medical Center

Target Recruit Count: 490

Registration Number: NCT05725512

Locations: 🇳🇱
Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands

Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS

Phase 2

Not yet recruiting

Conditions: Sjogren Syndrome With Other Organ Involvement

Interventions: Drug: Prednisolone
Drug: Tacrolimus

First Posted Date: 2023-01-23

Last Posted Date: 2023-01-23

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 110

Registration Number: NCT05694130

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

First Posted Date: 2023-01-09

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1875

Registration Number: NCT05675410

Locations: 🇺🇸
Naval Medical Center - Portsmouth, Portsmouth, Virginia, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 307 locations

The Treatment of Adrenal Crisis With Inhaled Prednisolone

Early Phase 1

Conditions: Adrenal Insufficiency

Interventions: Drug: Prednisolone

First Posted Date: 2022-12-06

Last Posted Date: 2022-12-06

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 12

Registration Number: NCT05639127

Locations: 🇳🇱
UMCG, Groningen, Netherlands

An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis

Phase 4

Recruiting

Conditions: Hypersensitivity Pneumonitis

Interventions: Drug: Mycophenolate Mofetil plus prednisolone
Drug: Prednisolone

First Posted Date: 2022-11-23

Last Posted Date: 2022-11-30

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 144

Registration Number: NCT05626387

Locations: 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India

Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19

Phase 3

Recruiting

Conditions: COVID-19 Associated Cardiac Involvement
Exercise Intolerance
Remodeling, Left Ventricle
Left Ventricular Dysfunction
Microvascular Angina
Remodeling, Vascular
Vascular Inflammation

Interventions: Drug: Prednisolone
Drug: Losartan

First Posted Date: 2022-11-17

Last Posted Date: 2023-09-21

Lead Sponsor: Valentina Puentmann

Target Recruit Count: 280

Registration Number: NCT05619653

Locations: 🇦🇹
University Medical Centre Vienna, Vienna, Austria
🇩🇪
Institute for experimental and translational cardiovascular imaging, Frankfurt Am Main, Hessen, Germany
🇩🇪
University Hospital Greifswald, Greifswald, Germany

and more 2 locations

Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

Phase 2

Recruiting

Conditions: Inflammatory Cardiomyopathy

Interventions: Drug: Mycophenolate Mofetil Placebo
Drug: Mycophenolate Mofetil
Drug: Prednisolone Placebo
Drug: Prednisolone

First Posted Date: 2022-10-06

Last Posted Date: 2024-08-16

Lead Sponsor: LMU Klinikum

Target Recruit Count: 130

Registration Number: NCT05570409

Locations: 🇩🇪
Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
🇩🇪
Charité - University Hospital Berlin, Berlin, Germany
🇩🇪
UHF- Universitäres Herz- und Gefässzentrum, Frankfurt, Germany

and more 11 locations

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

Phase 3

Recruiting

Conditions: Glomerulonephritis, IGA

Interventions: Drug: Prednisolone plus Cyclophosphamide
Drug: Prednisolone

First Posted Date: 2022-08-22

Last Posted Date: 2024-05-06

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 208

Registration Number: NCT05510323

Locations: 🇨🇳
AFMMU, Xi'an, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy